← Leaderboards
Michelle Jane Ormseth
Vanderbilt University
$1,267,350
Attributed
$1,267,350
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $507.3K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,267,350 · 3
VA$0 · 2
By mechanism
R21$575,999 · 1
P01$507,300 · 1
K23$184,051 · 1
I01$0 · 1
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- L Jackson Roberts$17,065,377
- Simon T Alford$5,940,388
- Gautam Bhave$2,693,396
- John A Oates$7,158,915
- David W Powell$2,096,605
Others in their field
Top investigators on “Autoimmune Diseases”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$303,553,812
- Barton F Haynes · Duke University$175,178,961
- Jeffrey P Krischer · University Of South Florida$145,926,425
- Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason$84,524,613
- Mark S Anderson · University Of California, San Francisco$70,760,032
- Robert S Negrin · Stanford University$48,464,292
Research focus
Autoimmune DiseasesInflammatoryAffectRheumatoid ArthritisRegulator GenesResponseInflammationProductionChronicInnovationMicrornasCardiovascular DiseasesCardiovascular Risk FactorCell TypeCell PhysiologyAtherosclerosisFutureCellsSerumStructureAutoimmunityPlayPreventVeterans
Grant awards (16)
Scavenging IsoLGs in Autoimmune Disease: a proof-of-concept clinical study$507,300
P01 · FY2025 · HL · contact PI
Small RNAs and risk of rheumatoid arthritis$0
I01 · FY2025 · VA · contact PI
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis$212,981
R21 · FY2024 · AR · contact PI
Small RNAs and risk of rheumatoid arthritis$0
I01 · FY2024 · VA · contact PI
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis$181,509
R21 · FY2023 · AR · contact PI
Small RNAs and risk of rheumatoid arthritis$0
I01 · FY2023 · VA · contact PI
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis$181,509
R21 · FY2022 · AR · contact PI
Small RNAs and risk of rheumatoid arthritis$0
I01 · FY2022 · VA · contact PI
Functional impact of HDL transport of microRNA in rheumatoid arthritis$0
IK2 · FY2021 · VA · contact PI
Functional impact of HDL transport of microRNA in rheumatoid arthritis$0
IK2 · FY2021 · VA · contact PI
Functional impact of HDL transport of microRNA in rheumatoid arthritis$0
IK2 · FY2019 · VA · contact PI
Functional impact of HDL transport of microRNA in rheumatoid arthritis$0
IK2 · FY2018 · VA · contact PI
Functional impact of HDL transport of microRNA in rheumatoid arthritis$0
IK2 · FY2017 · VA · contact PI
Functional Impact of HDL transport of miRNA in rheumatoid arthritis$59,122
K23 · FY2016 · AR · contact PI
Functional Impact of HDL transport of miRNA in rheumatoid arthritis$89,836
K23 · FY2015 · AR · contact PI
Functional Impact of HDL transport of miRNA in rheumatoid arthritis$35,093
K23 · FY2015 · AR · contact PI